Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2009 Oct–Dec;23(4):352–356. doi: 10.1097/WAD.0b013e31819e0cac

Table 1.

Perceived Benefits and Barriers by Likelihood to Refer to Clinical Trials and Medical Specialty

Likelihood to refer to clinical trial Medical Specialty
BENEFITS (%) Not likely
(n=162)
Likely
(n=193)
p-value PCP
(n=229)
Specialist
(n=141)
p-value
Patient and/or Family may benefit from participation 67.4 88.3 <.001 75.5 69.5 ns
Patient and/or Family is interested in research participation 73.6 84.0 .02 78.6 68.1 .03
Participation by the patient may enhance ongoing medical care 62.2 82.1 <.001 70.3 65.2 ns
I may receive helpful feedback to guide my care decisions 43.0 66.0 <.001 55.9 42.6 .01
BARRIERS (%)
The risks of participation appear to be too great 63.2 72.8 ns 67.7 58.9 ns
Patient may be unable to give informed consent 51.8 51.2 ns 53.7 41.8 .03
Patient may be exposed to uncomfortable procedures or risks 45.6 50.6 ns 50.7 37.6 .02
Family may find participation too overly burdensome 62.2 66.7 ns 61.6 60.3 ns
Not practical based on distance of my patient from the research site 55.4 59.3 ns 66.7 44.7 .004
Patient has expressed no interest in research 46.1 43.2 ns 44.1 40.4 ns
Lack of awareness of research studies 45.1 43.2 ns 41.9 42.6 ns
Lack of time to discuss research participation during clinical visits 43.0 35.8 ns 42.8 29.1 .008

PCP = Primary Care Provider

Ns = not significant